Clinical commercialization of a clonal cell line - NK92

被引：0
|
作者：
Keller, G
Klingemann, H
Tonn, T
LeFever, A
Borys, M
Palazzolo, M
Domanik, R
机构：
[1] ZelleRx Corp, Chicago, IL USA
[2] St Lukes Med Ctr, Dept Immunotherapy, Aurora Healthcare, Milwaukee, WI USA
[3] Abbott Labs, Specialty Prod Div, N Chicago, IL 60064 USA
[4] Inst Transfus Med & Hematol, Red Cross Blood Donor Serv, Frankfurt, Germany
[5] IIT, Stuart Grad Sch Business, Chicago, IL 60616 USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2003年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [1] Clinical commercialization of a clonal cell line NK-92 - Leveraging corporate development.
    Keller, G
    LeFever, A
    Domanik, R
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : S59 - S59
  • [2] Kinetics of cytokine regulation in human NK92 lymphoma cell line.
    Brown, BR
    Kurago, ZB
    JOURNAL OF DENTAL RESEARCH, 2002, 81 : A300 - A300
  • [3] Cost efficient and effective gene transfer into the human natural killer cell line, NK92
    Grund, EM
    Muise-Helmericks, RC
    JOURNAL OF IMMUNOLOGICAL METHODS, 2005, 296 (1-2) : 31 - 36
  • [4] Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92
    Tonn, T
    Becker, S
    Esser, R
    Schwabe, D
    Seifried, E
    JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (04): : 535 - 544
  • [5] Novaferon gene modification promotes NK92 cell anti-tumor activity
    Zhang, Wanze
    Yu, Bingxin
    Meng, Qingyu
    Pu, Luya
    Liu, Bin
    Li, Fan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122
  • [6] TOWARDS ENGINEERED NK CELL THERAPY: mRNA TRANSFECTION OF NK92 CELLS BY PHOTOPORATION WITH BIODEGRADABLE POLYDOPAMINE NANOSENSITIZERS
    Hinnekens, C.
    Harizaj, A.
    Goemare, I.
    De Smedt, S. C.
    Vandekerckhove, B.
    Fraire, J.
    Braeckmans, K.
    CYTOTHERAPY, 2023, 25 (06) : S228 - S228
  • [7] Re-targeting of an NK cell line (NK92) with specificity for CD19 efficiently kills human B-precursor leukemia cells.
    Romanski, A
    Uherek, C
    Bug, G
    Muller, T
    Rossig, C
    Kampfmann, M
    Krossok, N
    Hoelzer, D
    Seifried, E
    Wels, W
    Ottmann, OG
    Tonn, T
    BLOOD, 2004, 104 (11) : 751A - 751A
  • [8] NK92 cells and peripheral blood NK cells respond oppositely upon dasatinib treatment
    Li, Fengqi
    Wang, Zhongyi
    Zheng, Dongpeng
    Pang, Zhaojun
    Feng, Chunjing
    Ma, Yue
    Yang, Ce
    Li, Xueren
    Peng, Shouchun
    Liu, Zichuan
    Mu, Xin
    IMMUNOLOGY, 2024, 172 (01) : 163 - 177
  • [9] PHOTOPORATION OF NK92 CELLS WITH BIODEGRADABLE POLYDOPAMINE NANOSENSITIZERS AS A PROMISING STRATEGY FOR THE GENERATION OF CAR-NK CELL THERAPIES.
    Hinnekens, C.
    Harizaj, A.
    Goemaere, I.
    Berdecka, D.
    De Smedt, S.
    Vandekerckhove, B.
    Fraire, J.
    Braeckmans, K.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A34 - A35
  • [10] Exploring the T-cell-receptor redirected CD3+ natural killer cell line NK92 for adoptive immunotherapy to acute myeloid leukemia
    Wernersbach, J.
    Khan, S.
    Bhatti, A.
    Theobald, M.
    Hartwig, U. F.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 263 - 263
12345